Diversity in the oxidation of substrates by cytochrome P450 2D6:: Lack of an obligatory role of aspartate 301 -: Substrate electrostatic bonding

被引:51
作者
Guengerich, FP
Miller, GP
Hanna, IH
Martin, MV
Léger, S
Black, C
Chauret, N
Silva, JM
Trimble, LA
Yergey, JA
Nicoll-Griffith, DA
机构
[1] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA
[3] Merck Frosst Ctr Therapeut Res, Dept Med Chem, Quebec City, PQ H9H 4P8, Canada
关键词
D O I
10.1021/bi020341k
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cytochrome P450 (P450) 2136 was first identified as the polymorphic human debrisoquine hydroxylase and subsequently shown to catalyze the oxidation of a variety of drugs containing a basic nitrogen. Residue Asp301 has been characterized as being involved in electrostatic interactions with substrates on the basis of homology modeling and site-directed mutagenesis experiments [Ellis, S. W., Hayhurst, G. P., Smith, G., Lightfoot, T., Wong, M. M. S., Simula, A. P., Ackland, M. J., Sternberg, M. J. E., Lennard, M. S., Tucker, G. T., and Wolf, C. R. (1995) J. Biol. Chem. 270,29055-29058]. However, pharmacophore models based on the role of Asp301 in substrate binding are compromised by reports of catalytic activity toward substrates devoid of a basic nitrogen, which have generally been ignored. We characterized a high-affinity ligand for P450 2136, also devoid of a basic nitrogen atom, spirosulfonamide [4-[3-(4-fluorophenyl)-2-oxo-1-oxaspiro[4.4]non-3-en-4-yl]benzenesulfonamide], with K-s 1.6 muM. Spirosulfonamide is a substrate for P450 2136 (k(cat) 6.5 min(-1) for the formation of a syn spiromethylene carbinol, K-m 7 muM). Mutation of Asp301 to neutral residues (Asn, Ser, Gly) did not substantially affect the binding of spirosulfonamide (K-s 2.5-3.5 muM). However, the hydroxylation of spirosulfonamide was attenuated in these mutants to the same extent (90%) as for the classic nitrogenous substrate bufuralol, and the effect of the D301N substitution was manifested on k(cat) but not K-m. Analogues of spirosulfonamide were also evaluated as ligands and substrates. Analogues in which the sulfonamide moiety was modified to an amide, thioamide, methyl sulfone, or hydrogen were ligands with K-s values of 1.7-32 muM. All were substrates, and the methyl sulfone analogue was oxidized to the syn spiromethylene carbinol analogue of the major spirosulfonamide product. The D301N mutation produced varying changes in the oxidation patterns of the spirosulfonamide analogues. The peptidometic ritonavir and the steroids progesterone and testosterone had been reported to be substrates for P450 2136, but the affinities (K-s) were unknown; these were estimated to be 1.2, 1.5, and 15 muM, respectively (cf. 6 muM for the classic substrate bufuralol). The results are consistent with a role of Asp301 other than electrostatic interaction with a positively charged ligand. H-Bonding or electrostatic interactions probably enhance binding of some substrates, but our results show that it is not required for all substrates and explain why predictive models fail to recognize the proclivity for many substrates, especially those containing no basic nitrogen.
引用
收藏
页码:11025 / 11034
页数:10
相关论文
共 64 条
  • [1] Black C., 2001, Patent No. [US6222048, 6222048]
  • [2] EQUILIBRIUM ACIDITIES IN DIMETHYL-SULFOXIDE SOLUTION
    BORDWELL, FG
    [J]. ACCOUNTS OF CHEMICAL RESEARCH, 1988, 21 (12) : 456 - 463
  • [3] Busby WF, 1999, DRUG METAB DISPOS, V27, P246
  • [4] Chauret N, 1998, DRUG METAB DISPOS, V26, P1
  • [5] CHAURET N, 1994, DRUG METAB DISPOS, V22, P65
  • [6] CORREIA MA, 1995, CYTOCHROME P450 STRU, P607
  • [7] INVOLVEMENT OF CYP2D6, CYP3A4, AND OTHER CYTOCHROME-P-450 ISOZYMES IN N-DEALKYLATION REACTIONS
    COUTTS, RT
    SU, P
    BAKER, GB
    [J]. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 1994, 31 (04) : 177 - 186
  • [8] PROTONATION ACIDITY CONSTANTS FOR SOME BENZAMIDES, ACETAMIDES, AND LACTAMS
    COX, RA
    DRUET, LM
    KLAUSNER, AE
    MODRO, TA
    WAN, P
    YATES, K
    [J]. CANADIAN JOURNAL OF CHEMISTRY-REVUE CANADIENNE DE CHIMIE, 1981, 59 (11): : 1568 - 1573
  • [9] COMPARISON OF SUBSTRATE METABOLISM BY WILD-TYPE CYP2D6 PROTEIN AND A VARIANT CONTAINING METHIONINE, NOT VALINE, AT POSITION-374
    CRESPI, CL
    STEIMEL, DT
    PENMAN, BW
    KORZEKWA, KR
    FERNANDEZSALGUERO, P
    BUTERS, JTM
    GELBOIN, HV
    GONZALEZ, FJ
    IDLE, JR
    DALY, AK
    [J]. PHARMACOGENETICS, 1995, 5 (04): : 234 - 243
  • [10] Nomenclature for human CYP2D6 alleles
    Daly, AK
    Brockmoller, J
    Broly, F
    Eichelbaum, M
    Evans, WE
    Gonzalez, FJ
    Huang, JD
    Idle, JR
    IngelmanSundberg, M
    Ishizaki, T
    JacqzAigrain, E
    Meyer, UA
    Nebert, DW
    Steen, VM
    Wolf, CR
    Zanger, UM
    [J]. PHARMACOGENETICS, 1996, 6 (03): : 193 - 201